Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drugging the Undruggable: Advances on RAS Targeting in Cancer
Míriam Molina‐Arcas, Amit Samani, Julian Downward
Genes (2021) Vol. 12, Iss. 6, pp. 899-899
Open Access | Times Cited: 68

Showing 26-50 of 68 citing articles:

Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway
Xuenan Hou, Chishun Zhou, Zuhui Liang, et al.
Phytomedicine (2023) Vol. 121, pp. 155093-155093
Open Access | Times Cited: 10
Mechanism-Based Redesign of GAP to Activate Oncogenic Ras
Dénes Berta, Sascha Gehrke, Kinga Nyíri, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 37, pp. 20302-20310
Open Access | Times Cited: 9
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS mutations
Gerald P. Linette, Adham S. Bear, Beatriz M. Carreno
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2017-2024
Open Access | Times Cited: 3
Regulating Protein–RNA Interactions: Advances in Targeting the LIN28/Let-7 Pathway
Greater Kayode Oyejobi, Xiaodan Yan, Piotr Sliz, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3585-3585
Open Access | Times Cited: 3
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
Ali Chour, Anne‐Claire Toffart, E. Berton, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers
Johanna Lilja, Jasmin Kaivola, James R. W. Conway, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
RNA Therapy for Oncogenic NRAS-Driven Nevi Induces Apoptosis
Dale Bryant, Sara Barberan-Martin, Ruhina Maeshima, et al.
Journal of Investigative Dermatology (2024)
Open Access | Times Cited: 2
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96
Randa Mahran, Jonas N. Kapp, Salla Valtonen, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 10, pp. 2152-2164
Closed Access | Times Cited: 2
Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers
Tingkai Chen, Xu Tang, Zhenqi Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115828-115828
Closed Access | Times Cited: 6
Targeting RAS in neuroblastoma: Is it possible?
Lei Lin, Lei Miao, Huiran Lin, et al.
Pharmacology & Therapeutics (2021) Vol. 236, pp. 108054-108054
Closed Access | Times Cited: 15
KRAS Inhibitor that Simultaneously Inhibits Nucleotide Exchange Activity and Effector Engagement
Cynthia V. Pagba, Amit K. Gupta, Ali Naji, et al.
ACS Bio & Med Chem Au (2022) Vol. 2, Iss. 6, pp. 617-626
Open Access | Times Cited: 8
Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells
Naushin L. Hindul, Lauren R. Abbott, Sumaya M D Adan, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 6, pp. 107409-107409
Open Access | Times Cited: 1
Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor–induced immune responses
Megan Cole, Panayiotis Anastasiou, Claudia Lee, et al.
Science Advances (2024) Vol. 10, Iss. 44
Open Access | Times Cited: 1
Probing the KRas Switch II Groove by Fluorine NMR Spectroscopy
D. Matthew Peacock, Mark J. S. Kelly, Kevan M. Shokat
ACS Chemical Biology (2022) Vol. 17, Iss. 10, pp. 2710-2715
Open Access | Times Cited: 7
Adding recombinant AAVs to the cancer therapeutics mix
Patrick L. Mulcrone, Roland W. Herzog, Weidong Xiao
Molecular Therapy — Oncolytics (2022) Vol. 27, pp. 73-88
Open Access | Times Cited: 6
Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI
Simona-Ruxandra Volovat, Iolanda Augustin, Daniela Zob, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4834-4834
Open Access | Times Cited: 6
Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways
Pragya Tripathi, Ravi Soni, Antra, et al.
Free Radical Biology and Medicine (2022) Vol. 190, pp. 351-362
Open Access | Times Cited: 5
Targeting Oncogenic Driver Mutations in Lung Cancer
Matthew Lee, Fawzi Abu Rous, Alain Borczuk, et al.
(2023)
Closed Access | Times Cited: 2
Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse
Aria Vaishnavi, Conan G. Kinsey, Martin McMahon
Cold Spring Harbor Perspectives in Medicine (2023) Vol. 14, Iss. 1, pp. a041385-a041385
Closed Access | Times Cited: 2
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
Mariaserena Giliberto, Leonardo Miranda Santana, Toril Holien, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 4
Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses
Megan Cole, Panayiotis Anastasiou, Claudia Lee, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Therapeutic Targeting of KRAS Oncogene in Pancreatic Ductal Adenocarcinoma (PDAC)
Jeffrey Song
Journal of Student Research (2024) Vol. 13, Iss. 1
Open Access
KRAS degraders
Frantz Jean-François
Elsevier eBooks (2024), pp. 247-274
Closed Access
Association between KRAS mutation and alcohol consumption in Brazilian patients with colorectal cancer
Bianca Gomes‐Fernandes, Luísa Martins Trindade, Marcela de Castro Bastos Rodrigues, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Redesigned GAP to activate oncogenic GAP
Dénes Berta, Sascha Gehrke, Kinga Nyíri, et al.
(2023)
Open Access | Times Cited: 1

Scroll to top